INSM
INSMED Inc
Key Financials
Net Income
$-1276775000
↓ 39.7%
Operating Income
$-1246769000
↓ 42.0%
Gross Profit
$112.3M
↑ 203.4%
Revenue
$606.4M
↑ 66.7%
Total Liabilities
$1.5B
↓ 12.3%
Cash & Equivalents
$510.4M
↓ 8.0%
Shareholders' Equity
$739.0M
↑ 158.9%
EPS (Diluted)
$-6.42
↓ 15.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/11/2026 | View on SEC |
| 144 | 9/10/2026 | View on SEC |
| 4 | 8/19/2026 | View on SEC |
| 144 | 8/17/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
| 4 | 8/7/2026 | View on SEC |
| 144 | 8/6/2026 | View on SEC |
| SCHEDULE 13G/A | 8/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INSM |
| Company Name | INSMED Inc |
| CIK | 1104506 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | VA |
| Phone | 908-977-9900 |